ORGO
NASDAQ
US
Organogenesis Holdings Inc. - Class A
$2,24
▼ $-0,07
(-3,03%)
Vol. 507K
12
Punteggio di Qualità
ok
Analisi approfondita
1/5
fail
Ricavi ✗
Utile netto ✓
>IPO ✗
Cap. mercato
$657.4M
P/E
654,1
ROE
0,3%
Margine
0,2%
D/E
0,86
Beta
1,50
52W
$3–$7
Consenso Wall Street
7 analisti · Apr 20263
Acquisto forte
3
Compra
1
Mantieni
0
Vendi
0
Vendita forte
85,7%
Rating Compra
Grafico dei Prezzi
Titoli simili
CLYM
Climb Bio Inc
$272.7M
RZLT
Rezolute Inc
$218.8M
OVID
Ovid Therapeutics Inc
$116.1M
FHTX
Foghorn Therapeutics Inc
$305.4M
NBP
NovaBridge Biosciences
$458.9M
AVXL
Anavex Life Sciences Corp
$318.1M
TARA
Protara Therapeutics Inc
$275.2M
CCCC
C4 Therapeutics Inc
$185.1M
ABEO
Abeona Therapeutics Inc
P/E 3,5
$285.6M
Utili
Tasso di battuta: 50,0%
Prossimo report
Mag 06, 2026
Stima EPS: $-0,30
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,30 | — | — |
| Dic 2025 | $0,21 | $0,31 | +$0,10 |
| Set 2025 | $0,06 | $0,15 | +$0,09 |
| Giu 2025 | $-0,06 | $-0,10 | $-0,04 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $126.7M | $86.7M | $100.8M | $150.5M | $225.1M |
| Utile netto | — | $7.7M | -$18.8M | -$9.4M | $21.6M | $43.7M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -2.4% | -2.4% | -2.4% | -2.4% | 0.3% | 0.3% |
| P/E (TTM) | — | — | — | — | 635.19 | 654.13 |
| Net Margin | -9.3% | -1.9% | -1.9% | -1.9% | 0.2% | 0.2% |
| Gross Margin | 72.6% | 74.6% | 74.6% | 74.6% | 74.5% | 74.5% |
| D/E Ratio | 0.36 | 0.36 | 0.36 | 0.36 | 0.86 | 0.86 |
| Current Ratio | 3.95 | 3.95 | 3.95 | 3.95 | 3.32 | 3.32 |
Rapporti chiave
ROA (TTM)
0,2%
P/S (TTM)
1,41
P/B
1,0
EPS (TTM)
$0,00
CF/Share
$0,20
Crescita ricavi 3A
+1,0%
52W High
$7,08
52W Low
$2,61
$2,61
Intervallo 52 settimane
$7,08
Salute finanziaria
Flusso di cassa libero
$34.8M
Debito netto
-$11.5M
Liquidità
$93.7M
Debito totale
$82.1M
Aggiornato al Dic 31, 2025
Як ORGO виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка ORGO vs аналоги Biotechnology
P/E
654,1
▲
3383%
sopra
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
1,4
▼
89%
sotto
peer
(12,9)
vs Peer
vs Settore
Sottovalutato
P/B
1,0
▼
58%
sotto
peer
(2,5)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість ORGO vs аналоги Biotechnology
ROE
0,3%
▲
100%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Top livello
Net margin
0,2%
▲
100%
sopra
peer
(-286,8%)
vs Peer
vs Settore
Sotto media
Валова маржа
74,5%
▼
5%
sotto
peer
(78,6%)
vs Peer
vs Settore
Debole
ROA
0,2%
▲
100%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя ORGO vs аналоги Biotechnology
D/E ratio
0,9
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
In linea
Поточна ліквідність
3,3
▼
25%
sotto
peer
(4,4)
vs Peer
vs Settore
Liquidità bassa
Beta
1,5
▲
54%
sopra
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів ORGO
ORGO
Mediana peer
Industria
ORGO прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
ORGO vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
LEIBOWITZ ARTHUR S
Director · Mar 09
5000 shs
DRISCOLL MICHAEL JOSEPH
Director · Mar 09
10000 shs
KORFIN MICHELE ILENE
Director · Feb 18
48828 shs
DURAIBABU PRATHYUSHA
Director · Feb 18
48828 shs
FRANCISCO DAVID
Chief Financial Officer · Feb 18
238914 shs
FRANCISCO DAVID
Chief Financial Officer · Feb 18
239352 shs
DRISCOLL MICHAEL JOSEPH
Director · Feb 18
48828 shs
QUINTERO GILBERTO
Director · Feb 18
48828 shs
CAVORSI ROBERT
Officer · Feb 18
110204 shs
LUSTIG GARRETT
Director · Feb 18
48828 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 28,66%Morgan Stanley
9,05%
$26.7M
Soleus Capital Management, …
7,76%
$22.9M
Assenagon Asset Management …
4,30%
$12.7M
Vanguard Group Inc
3,85%
$11.4M
Blackrock Inc.
3,70%
$10.9M
Aggiornato al Dic 31, 2025